Shah R, et al. - The researchers determined the adherence to the screening guidelines recommending screening for hepatitis B virus (HBV) infection prior to initiating treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor (anti-TNF) therapy. In addition, they looked for clinical outcomes of HBV reactivation following anti-TNF use. It was a retrospective cohort study utilizing the Veterans Health Administration datasets for IBD patients with filled prescriptions for anti-TNFs from 2003 to 2011. They observed that HBV screening rates prior to anti-TNF initiation were low among IBD patients, but had increased over time. Clinically significant HBV reactivation after anti-TNF initiation in this US cohort was nonexistent despite low rates of screening.